8-K: CVRx Reports Q2 2025 Results, Appoints New COO

CVRx, Inc. announced its second quarter 2025 financial results, reporting a 15% revenue increase and the appointment of Brent Binkowski as Chief Operating Officer.

Summary

• Total revenue for the second quarter of 2025 was $13.6 million, a 15% increase over the prior year quarter.
• U.S. Heart Failure (HF) revenue for Q2 2025 was $12.1 million, also up 15% year-over-year.
• Active U.S. implanting centers grew to 240 as of June 30, 2025, a 27% increase since June 30, 2024.
• Gross profit for Q2 2025 was $11.5 million, a 16% increase, with gross margin remaining stable at 84%.
• Net loss for Q2 2025 was $14.7 million, or $0.57 per share, compared to a net loss of $14.0 million, or $0.65 per share, in Q2 2024.
• Cash and cash equivalents stood at $95.0 million as of June 30, 2025.
• Net cash used in operating and investing activities improved to $8.0 million in Q2 2025 from $10.2 million in Q2 2024.
• Brent Binkowski was appointed Chief Operating Officer, effective August 11, 2025, with an annual base salary of $405,000 and equity awards.
• CMS proposed to maintain Barostim implant procedure in New Technology APC 1580 for 2026 with a payment of approximately $45,000 for outpatient procedures.
• CMS proposed favorable physician fee payment levels for Category I CPT codes taking effect in 2026, with a national average physician payment of approximately $550 for the implant procedure.
• Full year 2025 revenue guidance was narrowed to between $55.0 million and $57.0 million (from $55.0M-$58.0M).
• Full year 2025 operating expense guidance was narrowed to between $96.0 million and $98.0 million (from $95.0M-$98.0M).
• Third quarter 2025 total revenue is expected to be between $13.7 million and $14.7 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Strong revenue growth, expanding market presence (active centers), and favorable reimbursement updates are significant positives. The appointment of a seasoned COO also adds to confidence. However, the continued net losses, increased operating expenses, and a slight downward adjustment to the top end of full-year revenue guidance temper the overall optimism.

Positives

• Total revenue increased by 15% to $13.6 million in Q2 2025, demonstrating continued growth.
• U.S. Heart Failure revenue also grew by 15% to $12.1 million, indicating strong domestic market penetration.
• The number of active U.S. implanting centers expanded significantly to 240, a 27% increase year-over-year, suggesting broader adoption of Barostim.
• Gross margin remained high and stable at 84%, reflecting efficient cost of goods sold.
• Net cash used in operating and investing activities decreased to $8.0 million from $10.2 million, indicating improved cash management.
• Favorable proposed CMS reimbursement updates for 2026, including maintaining Barostim in APC 1580 with a $45,000 payment and favorable physician fee levels for Category I CPT codes, are expected to improve future commercial efforts and payment predictability.
• The appointment of Brent Binkowski as Chief Operating Officer strengthens the management team with over 20 years of medical device leadership experience.

Negatives

• Net loss increased to $14.7 million in Q2 2025 from $14.0 million in Q2 2024, indicating continued unprofitability.
• Selling, general and administrative (SG&A) expenses increased by 11% to $23.4 million, primarily due to higher compensation and travel expenses.
• Interest expense increased by $0.5 million due to higher borrowings under the term loan agreement.
• Full year 2025 revenue guidance was narrowed, with the upper end slightly reduced from $58.0 million to $57.0 million, suggesting a more conservative outlook.

Risks

• A history of significant losses is expected to continue.
• Limited operating history as a commercial company and dependence on Barostim as a single product.
• Challenges in demonstrating the merits of Barostim to physicians and patients.
• Potential failure by third-party payors to provide adequate coverage and reimbursement for Barostim.
• Competitors developing and marketing products that are safer, more effective, less costly, easier to use, or more attractive than Barostim.
• Failure to gain access to hospitals for product use.
• Dependence on third-party manufacturers and suppliers, with a limited number of suppliers in some cases.
• Impacts from a pandemic, epidemic, or outbreak of an infectious disease.
• Exposure to product liability claims.
• Potential for expensive, time-consuming, and unsuccessful lawsuits to protect or enforce intellectual property.
• Risk of not retaining key executives or recruiting and hiring new employees.
• Impacts on adoption and regulatory approvals from additional long-term clinical data about the product.
• The final Medicare Hospital Outpatient Prospective Payment System (OPPS) rule for 2026 could differ from the proposed rule.
• The actual impact of the Ambulatory Payment Classification (APC) on reimbursement and patient access may vary from expectations.

Future Outlook

The company narrowed its full year 2025 revenue guidance to between $55.0 million and $57.0 million, and operating expense guidance to between $96.0 million and $98.0 million. For the third quarter of 2025, total revenue is expected to be between $13.7 million and $14.7 million. The company anticipates continued progress on clinical evidence strategy and strengthening reimbursement position, including favorable CMS proposals for 2026 regarding Barostim implant procedure payment and Category I CPT codes.

Management Comments

• "We delivered solid second quarter results and continued to build momentum across our business."
• "Our sales force transformation is gaining traction, and we're building sustainable Barostim programs with high potential centers."
• "We continue to make progress on multiple fronts by advancing our clinical evidence strategy and strengthening our reimbursement position, including CMS' proposal to keep Barostim in APC 1580 with appropriate payment for the implant procedure."
• "The fundamentals of our business remain strong, and our maturing commercial organization positions us well for continued growth."

Industry Context

CVRx operates in the neuromodulation medical device sector, specifically targeting cardiovascular diseases like heart failure. The company's focus on expanding active implanting centers and sales territories aligns with typical growth strategies for medical device companies introducing innovative, FDA-approved technologies. Favorable reimbursement proposals from CMS are critical for market adoption and revenue growth in the U.S. healthcare system, providing a positive signal for the broader medical device industry's ability to secure coverage for new technologies. The appointment of a COO with extensive medical device experience suggests a focus on scaling operations and R&D, common for commercial-stage companies in this space.

Comparison to Industry Standards

• NA

Management Changes

Stakeholder Impact

• Shareholders: Mixed impact with strong revenue growth and positive reimbursement outlook, but continued losses and a slight reduction in the top end of revenue guidance. The appointment of a new COO could be seen as a positive for operational efficiency.
• Patients: Continued expansion of active implanting centers and favorable reimbursement proposals suggest improved access to Barostim therapy for heart failure patients.
• Physicians: Favorable proposed physician fee payment levels for Category I CPT codes are expected to improve compensation and reduce administrative burdens related to prior authorizations.
• Employees: Increased compensation expenses in SG&A suggest ongoing investment in the sales force and general operations. The appointment of a new COO may lead to organizational restructuring in R&D, operations, regulatory affairs, and quality functions.

Next Steps

• CVRx will host a conference call to review its results at 4:30 p.m. Eastern Time on August 4, 2025.
• CMS is expected to publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November 2025.
• The transition to Category I CPT codes is set to take effect in January 2026.
• Brent Binkowski will join as Chief Operating Officer on August 11, 2025.

Key Dates

Recommendation

While CVRx demonstrates strong revenue growth, expanding market penetration, and favorable reimbursement developments for its Barostim product, the company continues to incur significant net losses. The slight narrowing of the full-year revenue guidance, even with positive operational momentum, suggests a cautious outlook. The appointment of a new COO is a positive step for operational scaling. For a seasoned investor, the company presents a growth story with substantial market opportunity, but also carries the inherent risks of a commercial-stage medical device company that is not yet profitable and relies on a single product. A 'hold' recommendation is appropriate to observe continued progress towards profitability and sustained market adoption, especially as the new CMS rules take effect in 2026.

Keywords

Medical Device, Neuromodulation, Heart Failure, Barostim, Cardiovascular Disease, SEC Filing, Financial Results, Q2 Earnings, CMS Reimbursement, CPT Codes, COO Appointment